Tacrolimus/mycophenolate mofetil improved natural killer lymphocyte reconstitution one year after kidney transplant by reference to cyclosporine/azathioprine

Transplantation

Volumn 82, Issue 4, 2006, Pages 558-566

  Vacher Coponat, Henri ^a   Brunet, Corinne ^a   Moal, Valérie ^a   Loundou, Andersen ^b   Bonnet, Elodie ^a   Lyonnet, Luc ^a   Ravet, Sophie ^a   Sampol Manos, Emmanuelle ^c   Sampol, José ^c   Berland, Yvon ^a,b   George, Françoise Dignat ^a   Paul, Pascale ^a,c  

^a HÔPITAL DE LA CONCEPTION   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

^c INSERM   (France)

Author keywords

Immunological monitoring; Immunosuppressive regimen; Kidney transplantation; Natural killer

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS; THYMOCYTE ANTIBODY;

ADULT; ARTICLE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; CYTOTOXICITY; FEMALE; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LYMPHOCYTE COUNT; LYMPHOCYTE FUNCTION; LYMPHOCYTE SUBPOPULATION; LYMPHOCYTOTOXICITY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NATURAL KILLER T CELL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; T LYMPHOCYTE;

EID: 33747884827     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000229390.01369.4a     Document Type: Article

References (37)

1. Vincenti F. A decade of progress in kidney transplantation. Transplantation 2004; 77 (9 Suppl): S52.
2. Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med 2004; 351(26): 2715.
3. Shapiro R, Young JB, Milford EL, et al. Immunosuppression: evolution in practice and trends, 1993-2003. Am J Transplant 2005; 5 (4 Pt 2): 874.
4. Starzl TE, Murase N, Abu-Elmagd K, et al. Tolerogenic immunosuppression for organ transplantation. Lancet 2003; 361(9368): 1502.
5. Hesselink DA, van Gelder T, van Schaik RH. The pharmacogenetics of calcineurin inhibitors: one step closer toward individualized immunosuppression? Pharmacogenomics 2005; 6(4): 323.
6. Hutchinson P, Chadban SJ, Atkins RC, Holdsworth SR. Laboratory assessment of immune function in renal transplant patients. Nephrol Dial Transplant 2003; 18(5): 983.
7. Thibaudin D, Alamartine E, Mariat C, et al. Long-term Kinetic of T-lymphocyte Subsets in Kidney-Transplant Recipients: Influence of Anti-T-cell Antibodies and Association with posttransplant Malignancies. Transplantation 2005(80): 1514.
8. Bravo Soto JA, Esteban de la Rosa RJ, Luna del Castillo JD, et al. Effect of mycophenolate mofetil regimen on peripheral blood lymphocyte subsets in kidney transplant recipients. Transplant Proc 2003; 35(4): 355.
9. Bisset LR, Lung TL, Kaelin M, et al. Reference values for peripheral blood lymphocyte phenotypes applicable to the healthy adult population in Switzerland. Eur J Haematol 2004; 72(3): 203.
10. Chng WJ, Tan GB, Kuperan P. Establishment of adult peripheral blood lymphocyte subset reference range for an Asian population by single-platform flow cytometry: influence of age, sex, and race and comparison with other published studies. Clin Diagn Lab Immunol 2004; 11(1): 168.
11. Santagostino A, Garbaccio G, Pistorio A, et al. An Italian national multicenter study for the definition of reference ranges for normal values of peripheral blood lymphocyte subsets in healthy adults. Haematologica 1999; 84(6): 499.
12. Jentsch-Ullrich K, Koenigsmann M, Mohren M, Franke A. Lymphocyte subsets' reference ranges in an age- and gender-balanced population of 100 healthy adults-A monocentric German study. Clin Immunol 2005; 116(2): 192.
13. Esteban de la Rosa RJ, Bravo Soto JA, Luna del Castillo JD, et al. Influence of age, sex, and hepatitis C virus infection on peripheral blood lymphocyte subsets in stable kidney transplantation. Transplant Proc 2003; 35(8): 2905.
14. Reichert T, DeBruyere M, Deneys V, et al. Lymphocyte subset reference ranges in adult Caucasians. Clin Immunol Immunopathol 1991; 60(2): 190.
15. Deenitchina SS, Ando T, Okuda S, et al. Cellular immunity in hemodialysis patients: a quantitative analysis of immune cell subsets by flow cytometry. Am J Nephrol 1995; 15(1): 57.
16. Bouts AH, Out TA, Schroder CH, et al. Characteristics of peripheral and peritoneal white blood cells in children with chronic renal failure, dialyzed or not. Perit Dial Int 2000; 20(6): 748.
17. Shabtai M, Avigad I, Schachter P, et al. Analysis of peripheral blood lymphocyte cell surface density of functional and activation associated markers in young and old hemodialysis patients. J Urol 1993; 150 (5 Pt 1): 1369.
18. Matsumoto Y. [Abnormalities of cellular immunity in uremic patients]. Nippon Jinzo Gakkai Shi 1993; 35(6): 733.
19. Bouts AH, Davin JC, Krediet RT, et al. Children with chronic renal failure have reduced numbers of memory B cells. Clin Exp Immunol 2004; 137(3): 589.
20. Nairn J, Hodge G, Henning P. Changes in leukocyte subsets: clinical implications for children with chronic renal failure. Pediatr Nephrol 2005; 20(2): 190.
21. Griveas I, Visvardis G, Fleva A, et al. Comparative analysis of immunophenotypic abnormalities in cellular immunity of uremic patients undergoing either hemodialysis or continuous ambulatory peritoneal dialysis. Ren Fail 2005; 27(3): 279.
22. Girndt M, Sester U, Sester M, et al. Impaired cellular immune function in patients with end-stage renal failure. Nephrol Dial Transplant 1999; 14(12): 2807.
23. Zand MS, Vo T, Huggins J, et al. Polyclonal rabbit antithymocyte globulin triggers B-cell and plasma cell apoptosis by multiple pathways. Transplantation 2005; 79(11): 1507.
24. Besancon-Watelet C, De March AK, Renoult E, et al. Early increase of peripheral B cell levels in kidney transplant recipients with CMV infection or reactivation. Transplantation 2000; 69(3): 366.
25. Hutchinson P, Jose M, Atkins RC, Holdsworth SR. Ex vivo lymphocyte proliferative function is severely inhibited in renal transplant patients on mycophenolate mofetil treatment. Transpl Immunol 2004; 13(1): 55.
26. Alamartine E, Berthoux F. [Natural killer lymphocytes in kidney transplantation]. Presse Med 1992; 21(41): 1957.
27. Vaessen LM, van Miert PP, van Gelder T, et al. Reassuring effect of pravastatin on natural killer cell activity in stable renal transplant patients. Transplantation 2001; 71(8): 1175.
28. Poggi A, Zocchi MR. Cyclosporin A regulates NK cell apoptosis induced by soluble HLA-I or by target cells. Autoimmun Rev 2005; 4(8): 532.
29. Webster A, Woodroffe R, Taylor R, et al. Tacrolimus vs. cyclosporin as primary immunosuppression for kidney transplant recipients. Cochrane Database Syst Rev 2005; 4: CD003961.
30. Parham P. MHC class I molecules and KIRs in human history, health and survival. Nat Rev Immunol 2005; 5(3): 201.
31. Ruggeri L, Mancusi A, Capanni M, et al. Exploitation of alloreactive NK cells in adoptive immunotherapy of cancer. Curr Opin Immunol 2005; 17(2): 211.
32. Tran TH, Mytilineos I, Scherer S, et al. Analysis of KIR Ligand Incompatibility in Human Renal Transplantation. Transplantation 2005; 80: 1121.
33. Kano Y, Shiohara T. Current understanding of cytomegalovirus infection in immunocompetent individuals. J Dermatol Sci 2000; 22(3): 196.
34. Labalette M, Salez F, Pruvot FR, et al. CD8 lymphocytosis in primary cytomegalovirus (CMV) infection of allograft recipients: expansion of an uncommon CD8+ CD57- subset and its progressive replacement by CD8+ CD57+ T cells. Clin Exp Immunol 1994; 95(3): 465.
35. Halary F, Pitard V, Dlubek D, et al. Shared reactivity of V{delta}2(neg) {gamma}{delta} T cells against cytomegalovirus-infected cells and tumor intestinal epithelial cells. J Exp Med 2005; 201(10): 1567.
36. Lafarge X, Merville P, Cazin MC, et al. Cytomegalovirus infection in transplant recipients resolves when circulating gammadelta T lymphocytes expand, suggesting a protective antiviral role. J Infect Dis 2001; 184(5): 533.
37. Kageyama S, Matsui S, Hasegawa T, et al. Augmentation of natural killer cell activity induced by cytomegalovirus infection in mice treated with FK506. Acta Virol 1997; 41(4): 215.